90Y-Ibritumomab Tiuxetan consolidation after autologous stem cell transplantation improves survival of patients with intermediate-/high-risk diffuse large B-cell lymphoma not responding adequately to first-line treatment
| Autor: | Patrizia Mondello, Pitini, V., Arrigo, C., Derenzini, E., Mian, M. |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2014 |
| Předmět: |
Adult
Male Y-90-Ibritumomab tiuxetan Hematopoietic Stem Cell Transplantation Antibodies Monoclonal salvage therapy DLBCL Middle Aged Transplantation Autologous Consolidation Chemotherapy Antibodies Monoclonal Murine-Derived Treatment Outcome Doxorubicin Vincristine Antineoplastic Combined Chemotherapy Protocols Humans Prednisone Female Lymphoma Large B-Cell Diffuse Rituximab Cyclophosphamide Follow-Up Studies Neoplasm Staging Retrospective Studies |
| Zdroj: | Scopus-Elsevier |
| Popis: | Diffuse large B-cell lymphoma (DLBCL) is the most common lymphoma entity whose prognosis for high-risk patients is poor. Aggressive salvage treatments to improve patient outcome have been unsatisfactory. Therefore, we evaluated the efficacy of yttrium-90-ibritumomab tiuxetan (Zevalin®; (90)Y-IT) consolidation after early salvage chemotherapy with autologous stem cell transplantation. Thirty-seven patients with intermediate-high risk DLBCL not in complete remission (CR) after three cycles of rituximab, cyclophosphomide, doxorubicin, vincristine and prednisone (R-CHOP) were assessed retrospectively. After early salvage treatment, 70% achieved CR and 30% partial remission. Twenty patients underwent additional consolidation with (90)Y-IT. During the 3-year follow-up, 50% in the (90)Y-IT-treated group experienced relapse compared to 82.3% in the other cohort (p=0.002). Progression- and disease-free survival were significantly longer in the (90)Y-IT group. However, probably due to the relatively short follow-up period, no difference in overall survival was observed. (90)Y-IT consolidation after early salvage chemotherapy improves treatment responses and reduces the percentage of relapses without significant additional toxicities. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|